{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T22:47:51Z","timestamp":1783982871028,"version":"3.55.0"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The combination of enfortumab vedotin and pembrolizumab (EVP) has recently revolutionized care for patients with previously untreated locally advanced and metastatic urothelial carcinoma. However, predictive biomarkers of response, the optimal duration of EVP for patients who respond well to therapy, and the role of circulating tumor DNA to monitor treatment response have not yet been fully elucidated. In this molecular tumor board, we summarize 6 patients from 4 different academic institutions with unresectable or oligometastatic urothelial carcinoma who achieved long-term remission on surveillance after a short duration of EVP treatment that resulted in complete response on follow-up imaging followed by consolidative radical cystectomy. We discuss potential predictive biomarkers for patients with exceptional response to EVP. These findings highlight the need to determine an optimal duration of EVP to maximize efficacy while minimizing adverse events. We aim to further define and explore the value of local therapy with consolidative cystectomy in the setting of unresectable, locally advanced, oligometastatic disease, or those with metastatic disease who achieve complete response of disease outside of the bladder. Identifying this subset of patients who may be candidates for this type of multidisciplinary management may result in durable treatment-free remission.<\/jats:p>","DOI":"10.1093\/oncolo\/oyaf259","type":"journal-article","created":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T11:28:58Z","timestamp":1755343738000},"source":"Crossref","is-referenced-by-count":2,"title":["Advanced urothelial carcinoma treated with enfortumab vedotin and pembrolizumab: a path to cure?"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0461-6174","authenticated-orcid":false,"given":"Albert","family":"Jang","sequence":"first","affiliation":[{"name":"Division of Solid Tumor Oncology, Department of Medicine, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine , Cleveland, OH 44106,","place":["United States"]},{"name":"Deming Department of Medicine, Tulane University School of Medicine , New Orleans, LA 70112,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikita","family":"Tripathi","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Department of Internal Medicine, Mayo Clinic , Phoenix, AZ 85054,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sree M","family":"Lanka","sequence":"additional","affiliation":[{"name":"Deming Department of Medicine, Tulane University School of Medicine , New Orleans, LA 70112,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamsa L S","family":"Kumar","sequence":"additional","affiliation":[{"name":"Division of Solid Tumor Oncology, Department of Medicine, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine , Cleveland, OH 44106,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prateek","family":"Jain","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Department of Internal Medicine, Mayo Clinic , Phoenix, AZ 85054,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6716-3806","authenticated-orcid":false,"given":"Adam","family":"Calaway","sequence":"additional","affiliation":[{"name":"Department of Urology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine , Cleveland, OH 44106,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan E","family":"Shoag","sequence":"additional","affiliation":[{"name":"Department of Urology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine , Cleveland, OH 44106,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7779-473X","authenticated-orcid":false,"given":"Randy","family":"Vince","sequence":"additional","affiliation":[{"name":"Department of Urology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine , Cleveland, OH 44106,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prateek","family":"Mendiratta","sequence":"additional","affiliation":[{"name":"Division of Solid Tumor Oncology, Department of Medicine, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine , Cleveland, OH 44106,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh","family":"Rao","sequence":"additional","affiliation":[{"name":"Division of Solid Tumor Oncology, Department of Medicine, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine , Cleveland, OH 44106,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge A","family":"Garcia","sequence":"additional","affiliation":[{"name":"Division of Solid Tumor Oncology, Department of Medicine, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine , Cleveland, OH 44106,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6225-7555","authenticated-orcid":false,"given":"Jason R","family":"Brown","sequence":"additional","affiliation":[{"name":"Division of Solid Tumor Oncology, Department of Medicine, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine , Cleveland, OH 44106,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2277-8668","authenticated-orcid":false,"given":"Vadim S","family":"Koshkin","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Hellen Diller Family Cancer Center, University of California San Francisco , San Francisco, CA 94158,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew T","family":"Campbell","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center , Houston, TX 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parminder","family":"Singh","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Department of Internal Medicine, Mayo Clinic , Phoenix, AZ 85054,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8890-2951","authenticated-orcid":false,"given":"Pedro C","family":"Barata","sequence":"additional","affiliation":[{"name":"Division of Solid Tumor Oncology, Department of Medicine, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine , Cleveland, OH 44106,","place":["United States"]},{"name":"Deming Department of Medicine, Tulane University School of Medicine , New Orleans, LA 70112,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,19]]},"reference":[{"key":"2025091915392073700_oyaf259-B1","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"2025091915392073700_oyaf259-B2","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.eururo.2017.09.030","article-title":"The role of surgery in metastatic bladder cancer: a systematic review","volume":"73","author":"Abufaraj","year":"2018","journal-title":"Eur Urol"},{"key":"2025091915392073700_oyaf259-B3","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.eururo.2025.05.015","article-title":"Consolidative surgery for advanced urothelial carcinoma following induction enfortumab vedotin and\/or immune checkpoint inhibitor therapy: a multicenter analysis","volume":"88","author":"Roberson","year":"2025","journal-title":"Eur Urol"},{"key":"2025091915392073700_oyaf259-B4","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.euros.2023.08.003","article-title":"Defining oligometastatic bladder cancer: a systematic review","volume":"55","author":"Bamias","year":"2023","journal-title":"Eur Urol Open Sci"},{"key":"2025091915392073700_oyaf259-B5","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.eururo.2023.05.005","article-title":"Definition and diagnosis of oligometastatic bladder cancer: a delphi consensus study endorsed by the European Association of Urology, European Society for Radiotherapy and Oncology, and European Society of Medical Oncology Genitourinary Faculty","volume":"84","author":"Bamias","year":"2023","journal-title":"Eur Urol"},{"key":"2025091915392073700_oyaf259-B6","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1001\/jamaoncol.2018.3542","article-title":"Downstaging and survival outcomes associated with neoadjuvant chemotherapy regimens among patients treated with cystectomy for muscle-invasive bladder cancer","volume":"4","author":"Peyton","year":"2018","journal-title":"JAMA Oncol"},{"key":"2025091915392073700_oyaf259-B7","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1200\/JCO.2023.41.6_suppl.531","article-title":"Pathologic response with neoadjuvant chemotherapy, immunotherapy, and chemo-immunotherapy for muscle-invasive bladder cancer (MIBC): a systematic review and meta-analysis","volume":"41","author":"Ayaz","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025091915392073700_oyaf259-B8","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1200\/JCO.2022.40.6_suppl.435","article-title":"Study EV-103 cohort H: antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients (pts) with muscle invasive bladder cancer (MIBC) who are cisplatin-ineligible","volume":"40","author":"Petrylak","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025091915392073700_oyaf259-B9","doi-asserted-by":"crossref","first-page":"683419","DOI":"10.3389\/fonc.2021.683419","article-title":"FDA-approved and emerging next generation predictive biomarkers for immune checkpoint inhibitors in cancer patients","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"key":"2025091915392073700_oyaf259-B10","doi-asserted-by":"crossref","first-page":"S1137","DOI":"10.1016\/j.annonc.2024.08.2051","article-title":"1966MO EV-302: exploratory analysis of nectin-4 expression and response to 1L enfortumab vedotin (EV)+ pembrolizumab (P) in previously untreated locally advanced or metastatic urothelial cancer (la\/mUC)","volume":"35","author":"Powles","year":"2024","journal-title":"Ann Oncol."},{"key":"2025091915392073700_oyaf259-B11","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.humpath.2022.06.005","article-title":"Biological and clinical perspectives of TERT promoter mutation detection on bladder cancer diagnosis and management","volume":"133","author":"Cheng","year":"2023","journal-title":"Hum Pathol"},{"key":"2025091915392073700_oyaf259-B12","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.euf.2017.07.004","article-title":"Prognostic value of TERT alterations, mutational and copy number alterations burden in urothelial carcinoma","volume":"5","author":"Isharwal","year":"2019","journal-title":"Eur Urol Focus"},{"key":"2025091915392073700_oyaf259-B13","doi-asserted-by":"crossref","first-page":"e002127","DOI":"10.1136\/jitc-2020-002127","article-title":"TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor","volume":"9","author":"de Kouchkovsky","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025091915392073700_oyaf259-B14","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.clgc.2022.11.007","article-title":"Genomic and clinical prognostic factors in patients with advanced urothelial carcinoma receiving immune checkpoint inhibitors","volume":"21","author":"Chawla","year":"2023","journal-title":"Clin Genitourin Cancer"},{"key":"2025091915392073700_oyaf259-B15","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.euo.2024.12.006","article-title":"Genomic biomarkers associated with enfortumab vedotin outcomes for patients with advanced urothelial carcinoma: analysis of unite study data","volume":"8","author":"Jindal","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"2025091915392073700_oyaf259-B16","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1158\/1078-0432.CCR-22-1764","article-title":"Membranous nectin-4 expression frequently decreases during metastatic spread of urothelial carcinoma and is associated with enfortumab vedotin resistance","volume":"29","author":"Kl\u00fcmper","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2025091915392073700_oyaf259-B17","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1200\/JCO.23.01983","article-title":"Nectin4 amplification is frequent in solid tumors and predicts enfortumab vedotin response in metastatic urothelial cancer","volume":"42","author":"Kl\u00fcmper","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025091915392073700_oyaf259-B18","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.eururo.2024.06.002","article-title":"Circulating tumor DNA to assess minimal residual disease: versatile, but how valuable?","volume":"86","author":"Brown","year":"2024","journal-title":"Eur Urol"},{"key":"2025091915392073700_oyaf259-B19","doi-asserted-by":"crossref","first-page":"e2300131","DOI":"10.1200\/PO.23.00131","article-title":"Longitudinal monitoring of circulating tumor DNA to assess the efficacy of immune checkpoint inhibitors in patients with advanced genitourinary malignancies","volume":"7","author":"Jang","year":"2023","journal-title":"JCO Precis Oncol."}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf259\/64084968\/oyaf259.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/9\/oyaf259\/64084968\/oyaf259.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/9\/oyaf259\/64084968\/oyaf259.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T19:39:29Z","timestamp":1758310769000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf259\/8238171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,19]]},"references-count":19,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf259","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,8,19]]},"article-number":"oyaf259"}}